AR099306A1 - Composiciones farmacéuticas para el tratamiento de trastornos inflamatorios - Google Patents
Composiciones farmacéuticas para el tratamiento de trastornos inflamatoriosInfo
- Publication number
- AR099306A1 AR099306A1 ARP150100350A ARP150100350A AR099306A1 AR 099306 A1 AR099306 A1 AR 099306A1 AR P150100350 A ARP150100350 A AR P150100350A AR P150100350 A ARP150100350 A AR P150100350A AR 099306 A1 AR099306 A1 AR 099306A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- lubricant
- composition according
- compound
- weight
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 7
- 238000011282 treatment Methods 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 3
- 229940125904 compound 1 Drugs 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000000314 lubricant Substances 0.000 abstract 3
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 239000003085 diluting agent Substances 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- GNWCZBXSKIIURR-UHFFFAOYSA-N (2-docosanoyloxy-3-hydroxypropyl) docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCCCCCC GNWCZBXSKIIURR-UHFFFAOYSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000013632 homeostatic process Effects 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 229940047124 interferons Drugs 0.000 abstract 1
- 230000036244 malformation Effects 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000008019 pharmaceutical lubricant Substances 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 235000015112 vegetable and seed oil Nutrition 0.000 abstract 1
- 239000008158 vegetable oil Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201402070A GB201402070D0 (en) | 2014-02-07 | 2014-02-07 | Pharmaceutical compositions for the treatment of inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099306A1 true AR099306A1 (es) | 2016-07-13 |
Family
ID=50390571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100350A AR099306A1 (es) | 2014-02-07 | 2015-02-06 | Composiciones farmacéuticas para el tratamiento de trastornos inflamatorios |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10493158B2 (enExample) |
| EP (1) | EP3102213B1 (enExample) |
| JP (1) | JP6633531B2 (enExample) |
| AR (1) | AR099306A1 (enExample) |
| AU (1) | AU2015215044B2 (enExample) |
| CA (1) | CA2938217C (enExample) |
| DK (1) | DK3102213T3 (enExample) |
| ES (1) | ES2788671T3 (enExample) |
| GB (1) | GB201402070D0 (enExample) |
| HR (1) | HRP20200605T1 (enExample) |
| NZ (1) | NZ722403A (enExample) |
| TW (1) | TWI697330B (enExample) |
| UY (1) | UY35985A (enExample) |
| WO (1) | WO2015117980A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| CN105111206B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物e晶型及其制备方法 |
| CN105198877B (zh) * | 2015-09-18 | 2017-09-22 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物g晶型及其制备方法 |
| CN105218539B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物b晶型及其制备方法 |
| CN105198880B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物a晶型及其制备方法 |
| CN105198879B (zh) * | 2015-09-18 | 2017-09-22 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物c晶型及其制备方法 |
| CN105198878B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物f晶型及其制备方法 |
| CN105111207B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物d晶型及其制备方法 |
| CN105198876B (zh) * | 2015-09-18 | 2017-09-29 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物h晶型及其制备方法 |
| CN108366958A (zh) * | 2015-11-30 | 2018-08-03 | 安那卡药品公司 | 用于治疗炎症相关病症的局部药物制剂 |
| KR20180120273A (ko) * | 2016-03-21 | 2018-11-05 | 크리스탈 파마테크 씨오., 엘티디. | Jak 관련 질병 예방 또는 치료용 약물의 염산 결정성 형태 및 이의 제조 방법 |
| CA3043396A1 (en) | 2016-11-10 | 2018-05-17 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases |
| GB201702603D0 (en) | 2017-02-17 | 2017-04-05 | Galápagos Nv | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| JOP20180018A1 (ar) * | 2017-03-14 | 2019-01-30 | Gilead Sciences Inc | تركيبات صيدلية تتضمن مثبط jak |
| KR102738945B1 (ko) | 2018-03-01 | 2024-12-04 | 아스트라제네카 에이비이 | (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를 포함하는 약학 조성물 |
| GB201808575D0 (en) | 2018-05-24 | 2018-07-11 | Galapagos Nv | Methods for the treatment of psoriatic arthrits |
| KR20210032431A (ko) | 2018-07-17 | 2021-03-24 | 인스메드 인코포레이티드 | 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드 |
| TW202207940A (zh) * | 2020-04-14 | 2022-03-01 | 美商健生生物科技公司 | 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物 |
| CN120584108A (zh) | 2023-01-06 | 2025-09-02 | 英斯梅德股份有限公司 | 新型可逆dpp1抑制剂及其用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2228451T3 (es) | 1999-01-29 | 2005-04-16 | Chugai Seiyaku Kabushiki Kaisha | Promotores de condrogenesis y derivados de indolin-2-ona. |
| JPWO2002087620A1 (ja) | 2001-04-27 | 2004-08-12 | 中外製薬株式会社 | 軟骨形成促進剤 |
| US6514989B1 (en) | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| DE602004001676T2 (de) | 2003-02-14 | 2007-08-30 | Pfizer Products Inc., Groton | Triazolo-Pyridine als entzündungshemmende Verbindungen |
| US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| EP1759203A2 (en) | 2004-06-21 | 2007-03-07 | Galapagos N.V. | Methods and means for treatment of osteoarthritis |
| MX2007002050A (es) | 2004-08-18 | 2007-03-29 | Pharmacia & Upjohn Co Llc | Compuestos de triazolopiridina. |
| WO2006038116A2 (en) | 2004-10-07 | 2006-04-13 | Warner-Lambert Company Llc | Triazolopyridine derivatives as antibacterial agents |
| GB0515026D0 (en) | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| KR20130016386A (ko) * | 2005-08-10 | 2013-02-14 | 시오노기세이야쿠가부시키가이샤 | 구강내 붕괴 정제 |
| ES2549862T3 (es) | 2006-08-30 | 2015-11-02 | Cellzome Limited | Derivados de triazol como inhibidores de quinasa |
| PE20090370A1 (es) | 2007-06-05 | 2009-04-30 | Takeda Pharmaceutical | Derivados de heterociclo fusionado como inhibidores de quinasa |
| AU2008277628B2 (en) | 2007-07-18 | 2012-03-15 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
| WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
| AU2008291075A1 (en) | 2007-08-31 | 2009-03-05 | Merck Serono S.A. | Triazolopyridine compounds and their use as ask inhibitors |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| KR20110031475A (ko) | 2008-06-20 | 2011-03-28 | 제넨테크, 인크. | 트리아졸로피리딘 ｊａｋ 억제제 화합물 및 방법 |
| JO3041B1 (ar) * | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
| WO2010010187A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010184A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
| WO2010010186A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010189A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| CN102459258B (zh) | 2009-06-05 | 2015-11-25 | 赛福伦公司 | 1,2,4-三唑并[1,5a]吡啶衍生物的制备和用途 |
| TWI462920B (zh) * | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
| US20130310340A1 (en) * | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| MA37775A1 (fr) | 2012-06-22 | 2017-04-28 | Galapagos Nv | Aminotriazolopyridine pour l'utilisation dans le traitement de l'inflammation, et compositions pharmaceutiques associées |
| JP6041823B2 (ja) * | 2013-03-16 | 2016-12-14 | ファイザー・インク | トファシチニブの経口持続放出剤形 |
| GB201402071D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
-
2014
- 2014-02-07 GB GB201402070A patent/GB201402070D0/en not_active Ceased
-
2015
- 2015-02-04 NZ NZ72240315A patent/NZ722403A/en unknown
- 2015-02-04 JP JP2016550646A patent/JP6633531B2/ja active Active
- 2015-02-04 EP EP15705777.9A patent/EP3102213B1/en active Active
- 2015-02-04 HR HRP20200605TT patent/HRP20200605T1/hr unknown
- 2015-02-04 DK DK15705777.9T patent/DK3102213T3/da active
- 2015-02-04 AU AU2015215044A patent/AU2015215044B2/en active Active
- 2015-02-04 US US14/614,393 patent/US10493158B2/en active Active
- 2015-02-04 CA CA2938217A patent/CA2938217C/en active Active
- 2015-02-04 WO PCT/EP2015/052239 patent/WO2015117980A1/en not_active Ceased
- 2015-02-04 ES ES15705777T patent/ES2788671T3/es active Active
- 2015-02-06 UY UY0001035985A patent/UY35985A/es not_active Application Discontinuation
- 2015-02-06 AR ARP150100350A patent/AR099306A1/es unknown
- 2015-02-06 TW TW104104150A patent/TWI697330B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015215044A1 (en) | 2016-08-11 |
| CA2938217C (en) | 2023-03-07 |
| US20150224199A1 (en) | 2015-08-13 |
| TWI697330B (zh) | 2020-07-01 |
| HRP20200605T1 (hr) | 2020-07-10 |
| EP3102213A1 (en) | 2016-12-14 |
| JP6633531B2 (ja) | 2020-01-22 |
| JP2017505330A (ja) | 2017-02-16 |
| NZ722403A (en) | 2019-09-27 |
| DK3102213T3 (da) | 2020-05-04 |
| GB201402070D0 (en) | 2014-03-26 |
| EP3102213B1 (en) | 2020-04-01 |
| AU2015215044B2 (en) | 2020-04-09 |
| CA2938217A1 (en) | 2015-08-13 |
| UY35985A (es) | 2015-09-30 |
| ES2788671T3 (es) | 2020-10-22 |
| TW201613601A (en) | 2016-04-16 |
| US10493158B2 (en) | 2019-12-03 |
| WO2015117980A1 (en) | 2015-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR099306A1 (es) | Composiciones farmacéuticas para el tratamiento de trastornos inflamatorios | |
| CL2017002650A1 (es) | Compuestos novedosos | |
| GT201700107A (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y oesteoartritis | |
| CU20170077A7 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos, composiciones y combinaciones que lo comprende | |
| MX2016010068A (es) | Sales novedosas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios. | |
| CL2018001031A1 (es) | Inhibidores de ferroportina novedosos | |
| GT201600147A (es) | Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2 | |
| MX2016011036A (es) | Compuestos de éter para el tratamiento de trastornos mediados por complemento. | |
| CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| BR112018003026A2 (pt) | composições compreendendo um inibidor de pi3k e um inibidor de hdac | |
| MX2017007299A (es) | Composiciones en suspension de liberacion prolongada gastroretentivas. | |
| BR112018003212A2 (pt) | diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3 | |
| AR086042A1 (es) | Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica | |
| AR089960A1 (es) | Compuesto de imidazolopiridina para el tratamiento de enfermedades degenerativas e inflamatorias | |
| MX378866B (es) | Composiciones de azucar para la formacion de comprimidos por compresion directa. | |
| CR20160433A (es) | Nuevos compuestos | |
| MX2015009512A (es) | Dihidropirimidinonas biciclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofilica. | |
| PH12016501677A1 (en) | Benzimidazole derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| CL2017001720A1 (es) | Nuevos derivados de bencimidazol como agentes antihistamínicos. | |
| CL2017000153A1 (es) | Composiciones de azúcares para la formación de comprimidos mediante compresión directa | |
| ECSP15009391A (es) | siARN Y SU USO EN LOS MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE ENFERMEDADES DE LOS OJOS | |
| CO2017000745A2 (es) | Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrófila | |
| MX386902B (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| UA120075C2 (uk) | Фармацевтична композиція для лікування запальних змін прямої кишки |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |